News
Barchart on MSN3h
2 Outstanding ‘Strong Buy’ Stocks to Grab in August
For savvy investors looking for long-term businesses that not only dominate their industries today but also have the ...
Zacks Investment Research on MSN1d
Lilly Stock Down 5% This Month: Should You Buy the Dip?
Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on ...
Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...
The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.
CRISPR Therapeutics advances with promising CTX310 data and key clinical milestones ahead. Click here to read an analysis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback